PMS5 Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-to-Severe Rheumatoid Arthritis
Nov 1, 2012, 00:00 AM
10.1016/j.jval.2012.08.1360
https://www.valueinhealthjournal.com/article/S1098-3015(12)03073-2/fulltext
Section Title :
Muscular-Skeletal Disorders
Section Order :
857
First Page :
A439
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03073-2&doi=10.1016/j.jval.2012.08.1360